The use of statins in patients with type 2 diabetes mellitus
DOI:
https://doi.org/10.52556/2587-3873.2024.5(102).09Keywords:
cardiovascular disease`, diabetes mellitus type 2, dyslipidemia, statinsAbstract
Dyslipidemia is a major risk factor for the development of cardiovascular disease in people with diabetes. Achieving recommended therapeutic goals of LDL cholesterol (LDL-c, LDL-low density lipoproteins) reduces the risk of occurrence and progression of chronic complications of diabetes. A descriptive cross-sectional study was carried out on a number of 485 patients with type 2 diabetes, hospitalized in the Endocrinology department of Republican Clinical Hospital „Timofei Moșneaga” during september-november 2023. Of the 485 subjects included in the study, only 242 (49.9%) were taking statin treatment. The mean value of LDL-c in the group of patients taking statins was statistically significantly lower (3.16 mmol/l vs. 3.42 mmol/l; p<0.05). However, even in the group of subjects taking statins, the mean value of LDL-c far exceeds the value of therapeutic targets recommended for people with diabetes mellitus (DM). Personal history of myocardial infarction was reported by 35 (7.2%) study subjects, and of stroke by 14 (2.8%) study subject. But only 40% of those who suffered a heart attack and 50% who suffered a stroke were taking statins. The study highlighted that only half of the people with type 2 DM were administering lipid-lowering treatment with statins, but the therapeutic goals for LDL-c recommended for people with type 2 DM had not been reached.
References
1. American Diabetes Association. 9. Cardiovascular disease and risk management. In: Diabetes Care, 2017, nr.40, pp. 75-87. https://doi.org/10.2337/dc17-S012
2. American Diabetes Association. 10. Cardiovascular disease risk Management: Standarts of Care in Diabetes. In: Diabetes Care, 2024, nr. 47, pp. S179-S218 https://doi.org/10.2337/dc24-S010
3. BOEKHOLDT, S.M., HOVINGH, G.K., MORA, S., ARSENAULT, B.J., Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a metaanalysis of statin trials. In: J Am Coll Cardiol, 2014, nr. 64, pp. 485-494. https://doi.org/10.1016/j.jacc.2014.02.615
4. CHAIT, A., GOLDBERG, I. Treatment of dyslipidemia in diabetes: recent advances and remaining questions. In: Curr Diab Rep 2017, nr. 17, 112 p. https://doi.org/10.1007/s11892-017-0942-8
5. CHANG, L., DEVINDER, D., ZAKARIA, A. et al. Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in Highrisk Populations. In: JAMA Cardiology. 2022, nr.7, pp. 672-680. https://doi.org/10.1001/jamacardio.2022.0912
6. CHIESA ST, CHARAKIDA M, MCLOUGHLIN E., et al. Elevated high-density lipopro- tein in adolescents with type 1 diabetes is associated with endothelial dysfunction in the presence of systemic inflammation. In:Eur Heart J. 2019, nr. 40, pp. 3559-3566. https://doi.org/10.1093/eurheartj/ehz114
7. Cholesterol Treatment Trialists' (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. In: Lancet. 2012, nr. 380, pp. 581-590. https://doi.org/10.1016/S0140-6736(12)60367-5
8. Cholesterol Treatment Trialists' (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials. In: Lancet. 2012, nr. 380, pp. 581-590. https://doi.org/10.1016/S0140-6736(12)60367-5
9. Guidelines for the management of cardiovascular dis ease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). In: European Heart Journal. 2023, nr. 44, pp. 4043-4140. https://doi.org/10.1093/eurheartj/ehad774
10. FOX CS, GOLDEN SH, ANDERSON C, BRAY GA, BURKE LE, DE BOER IH, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific state ment from the American Heart Association and the American Diabetes Association. In: Circulation. 2015, nr. 32, pp. 691-718. https://doi.org/10.1161/CIR.0000000000000230
11. GUPTA, R., LODHA, S., SHARMA, K.K., et al. Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2. In: BMJ Open Diabetes Res Care. 2016, nr. 4, e000275. https://doi.org/10.1136/bmjdrc-2016-000275
12. Jeongmin, Lee , Seung-Hwan, Lee. Lipid variability in patients with diabetes mellitus. In: Cardiovascular Prevention and Pharmacotherapy , 2023, nr. 5, pp. 126-133. https://doi.org/10.36011/cpp.2023.5.e18
13. MALENE, K., MARTIN, B., KEVIN, K., et al. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and wellcontrolled LDL cholesterol: a cohort study. In: Lancet Regional Health- Europe.2024, nr.36, 100774 p. https://doi.org/10.1016/j.lanepe.2023.100774
14. MASHAD, H., ZAHRA, A., REZA, Z., et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. In: Lipids in Health and Disease, 2020, nr. 42
15. PATEL, KK., GOMES, MB., CHARBONNEL, B., et al. Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: insights from the DISCOVER study. In: Diabetes, Obes Metab. 2021 , nr. 23, pp. 39-48. https://doi.org/10.1111/dom.14180
16. RAY, K.K., HAQ, I., BILITOU, A., MANU, M.C., et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021:The multinational observational SANTORINI study. In: Lancet Reg. Health Eur, 2023, nr. 29, 100624 p. https://doi.org/10.1016/j.lanepe.2023.100624
17. SHINTARO, I., YOSHIRO, M., KOUTARO, Y. Updates of dyslipidemia in patients with diabetes. In: Journal of Diabetes Investigation, 2023 nr. 14, pp.1041-1044. https://doi.org/10.1111/jdi.14042
18. SHOSHANA, TELL, KRISTEN, J.N., ROBERT, H.E. Lipid management for cardiovascular risk reduction in type 1 diabetes. In: Curr Opin Endocrinol Diabetes Obes, 2020, nr. 27, pp. 207-214. https://doi.org/10.1097/MED.0000000000000551
19. TAYLOR, F., HUFFMAN, M.D., MACEDO, A.F., et al. Statins for the primary prevention of cardiovascular disease. In: Cochrane Database Syst Rev, 2013, CD004816 Google ScholarPubMed https://doi.org/10.1002/14651858.CD004816.pub5
20. VILLAR-TAIBO, R., FERNÁNDEZ-RODRÍGUEZ, E., TEJERA-PÉREZ, C., et al. GALIPDIA study: Reaching lipid targets in a population with type 2 diabetes (T2DM) from the Northwest of Spain. In: Endocrinol Diabetes Nutr, 2023, nr. 70, pp. 29-38. https://doi.org/10.1016/j.endinu.2022.06.009
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
